The South African Health Products Regulatory Authority is waiting for a response from Pfizer to approve an Omicron-specific booster. (Photo: forbes.com / Wikipedia)Pharmaceutical company Pfizer on Thursday announced that a trial for their Omicron-specific booster vaccine, aimed at fighting infections caused by the BA.4 and BA.5 subvariants, has shown great promise. The company added that the booster was well tolerated and had a safety profile similar to the original vaccine. Pfizer said that additional data measuring responses after a month of having received the booster vaccine are expected soon. The highest positivity rate was found in Gauteng (around 10%), followed by the Western Cape (8%) and Limpopo and the Eastern Cape, each on 7%.

Source: Forbes October 13, 2022 20:58 UTC